Meeting
2024 ASCO Annual Meeting
Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).
Authors
Bradley Alexander McGregor
Lank Center for Genitourinary Oncology, Boston, MA
Bradley Alexander McGregor , Lucia Kwak , Guru P. Sonpavde , Stephanie A. Berg , Toni K. CHOUEIRI , Joaquim Bellmunt , Charlene Mantia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04724018
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS4618)
DOI
10.1200/JCO.2024.42.16_suppl.TPS4618
Abstract #
TPS4618
Poster Bd #
307b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).
First Author: Michal Sternschuss
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.
First Author: Yohann Loriot
Poster
2024 ASCO Genitourinary Cancers Symposium
Evaluation of provider preferences in first-line metastatic cisplatin-ineligible urothelial carcinoma in the setting of platinum shortages.
First Author: Michael Seth Weinfeld
Poster
2023 ASCO Annual Meeting
Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.
First Author: Yohann Loriot